Clarametyx Biosciences, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2020-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.clarametyx.com
Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)A Study to Evaluate the Safety of CMTX-101 in People with Cystic Fibrosis
Phase 1
Recruiting
- Conditions
- Persistent InfectionCystic Fibrosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Clarametyx Biosciences, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT06159725
- Locations
- 🇺🇸
University of Alabama, Birmingham, Birmingham, Alabama, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸National Jewish Health, Denver, Colorado, United States
A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101
Phase 1
Terminated
- Conditions
- Community-acquired PneumoniaBacterial Pneumonia
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Clarametyx Biosciences, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT05629741
- Locations
- 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸Augusta University Health, Augusta, Georgia, United States
🇺🇸Snake River Research, PLLC, Idaho Falls, Idaho, United States
News
No news found